A next-generation vaccine that uses a weakened form of a malaria parasite has shown efficacy and safety in a small number of humans, according to a new study published in Science Translational Medicine. With this development, researchers of the vaccine called GAP3KO might have achieved a milestone in malaria vaccine development.
The study, as reported in medicalnewstoday.com reveals that GAP3KO stimulated an effective immune response against the deadly malaria parasite Plasmodium falciparum, without causing any serious side effects...Read More
Comments
Post a Comment